Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
Jerald Sadoff, Mathieu Le Gars, Boerries Brandenburg, Vicky Cárdenas, Georgi Shukarev, Nathalie Vaissière, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Mandy Jongeneelen, Krisztián Kaszás, Jeroen Tolboom, Gert C. Scheper, Jenny Hendriks, Javier Ruiz‐Guiñazú, Frank Struyf, Johan Van Hoof, Macaya Douoguih, Hanneke Schuitemaker
Topics & Concepts
MedicineNeutralizing antibodyPlaceboAntibodyInternal medicineCohortImmunologyBooster doseGastroenterologyRandomized controlled trialPharmacologyImmunizationPathologyAlternative medicineSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studiesvaccines and immunoinformatics approaches